Podrobno

Colicin insensitivity correlates with a higher prevalence of extraintestinal virulence factors among Escherichia coli isolates from skin and soft-tissue infections
ID Petkovšek, Živa (Avtor), ID Žgur-Bertok, Darja (Avtor), ID Starčič Erjavec, Marjanca (Avtor)

URLURL - Predstavitvena datoteka, za dostop obiščite http://dx.doi.org/10.1099/jmm.0.037234-0 Povezava se odpre v novem oknu

Jezik:Angleški jezik
Ključne besede:colicins, Escherichia coli, skin infections, soft-tissue infections
Vrsta gradiva:Delo ni kategorizirano
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:BF - Biotehniška fakulteta
Leto izida:2012
Št. strani:Str. 762-765
Številčenje:Vol. 61, no. Pt 6
PID:20.500.12556/RUL-37593 Povezava se odpre v novem oknu
UDK:579.6
ISSN pri članku:0022-2615
DOI:10.1099/jmm.0.037234-0 Povezava se odpre v novem oknu
COBISS.SI-ID:2552399 Povezava se odpre v novem oknu
Datum objave v RUL:10.07.2015
Število ogledov:2075
Število prenosov:404
Metapodatki:XML DC-XML DC-RDF
:
PETKOVŠEK, Živa, ŽGUR-BERTOK, Darja in STARČIČ ERJAVEC, Marjanca, 2012, Colicin insensitivity correlates with a higher prevalence of extraintestinal virulence factors among Escherichia coli isolates from skin and soft-tissue infections. Journal of medical microbiology [na spletu]. 2012. Vol. 61, no. Pt 6, p. 762–765. [Dostopano 1 april 2025]. DOI 10.1099/jmm.0.037234-0. Pridobljeno s: http://dx.doi.org/10.1099/jmm.0.037234-0
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of medical microbiology
Skrajšan naslov:J. Med. Microbiol.
Založnik:Livingstone, Society for General Microbiology
ISSN:0022-2615
COBISS.SI-ID:6511879 Povezava se odpre v novem oknu

Podobna dela

Podobna dela v RUL:
  1. Systematic review and meta-analysis of observational studies evaluating treatment outcomes in patients with metastatic non-small-cell lung cancer on first-line immune checkpoint inhibitors therapy
  2. Description of adverse event of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer treated at the University Clinic Golnik
  3. Effectivness and safety of immunotherapy in patients with advanced non-small cell lung cancer in second line treatment at the University Clinic Golnik
  4. Evaluation of possible pembrolizumab dosing regimen racionalisation in advanced non-small cell lung cancer
  5. ǂThe ǂpotential of immunotherapies in the treatment of lung cancer
Podobna dela v drugih slovenskih zbirkah:
  1. ǂThe ǂrole of immune checkpoint inhibitors in the treatment of cancer of unknown origin
  2. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA)
  3. Febrile neutropenia and grade 3/4 neutropenia in daily practice of adjuvant chemotherapy for non-small-cell lung cancer
  4. Advances in the therapy with immune-check point inhibitors (ICI) in non-small cell lung cancer (NSCLC) in 2022
  5. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Nazaj